Peak airway pressure during positive pressure ventilation (cm H₂O) · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
1 finding from 1 review
Oropharyngeal leak pressure (seal pressure) (cm H₂O) · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
1 finding from 1 review
Sore throat · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
ProSeal showed no clear difference in sore throat compared with classic laryngeal mask airway (LMA) (low certainty).
1 finding from 1 review
Regurgitation · adult patients (18 years of age and older) for positive pressure ventilation undergoing elective surgery
ProSeal showed no clear difference in regurgitation compared with classic laryngeal mask airway (LMA) (low certainty).
1 finding from 1 review
Intervention not reported
Acute exacerbations (number of exacerbations/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in acute exacerbations (number of exacerbations/person/year) (low certainty).
1 finding from 1 review
Intervention not reported
Mortality (deaths during trial period) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
It is very uncertain whether the intervention changes mortality (deaths during trial period) (very low certainty).
1 finding from 1 review
Intervention not reported
Antibiotic prescriptions (number of courses/person/year) **Corticosteroids not meta‐analysed · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention may leads to higher antibiotic prescriptions (number of courses/person/year)… (low certainty).
1 finding from 1 review
Intervention not reported
Hospital admissions (number of participants hospitalised during trial period) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Intervention not reported
Adverse events (number of adverse events/person/year) · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
The intervention showed no clear difference in adverse events (number of adverse events/person/year) (low certainty).
1 finding from 1 review
Intervention not reported
Quality of life Not meta‐analysed · adults (> 18 years of age) with either COPD or recurrent acute exacerbations of chronic bronchitis
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Pain duration (mean pain duration, assessed at 4 weeks) · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain duration (mean pain duration, assessed at 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain improvement (clinician judged, assessed at 2 weeks) · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain improvement (clinician judged, assessed at 2 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain episodes · Children with recurrent abdominal pain
It is very uncertain whether antispasmodics changes pain frequency (episodes of pain in 4 weeks, assessed after 4 weeks) compared with placebo (very low certainty).
1 finding from 1 review
Pain improvement (self reported response to treatment, assessed at 4 weeks) · Children with recurrent abdominal pain
Antispasmodics showed no clear difference in pain improvement (self reported response to treatment, assessed at 4… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Uncorrected visual acuity (UCVA) of 20/20 or better · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
It is very uncertain whether the intervention changes uncorrected visual acuity (UCVA) of 20/20 or better (very low certainty).
1 finding from 1 review
RR 0.96 [0.82, 1.13]
Studies not reported
Very low
Intervention not reported
Uncorrected visual acuity (UCVA) of 20/40 or better · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
It is very uncertain whether the intervention changes uncorrected visual acuity (UCVA) of 20/40 or better (very low certainty).
1 finding from 1 review
RR 0.9 [0.67, 1.21]
Studies not reported
Very low
Intervention not reported
Proportion of participants who lost two or more lines of best‐corrected visual acuity (BCVA) · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Eyes within ± 0.5 D of target refraction · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
It is very uncertain whether the intervention changes eyes within ± 0.5 D of target refraction (very low certainty).
1 finding from 1 review
RR 0.69 [0.48, 0.99]
Studies not reported
Very low
Intervention not reported
Postoperative corneal haze · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
It is very uncertain whether the intervention changes postoperative corneal haze (very low certainty).
1 finding from 1 review
RR 2.11 [0.57, 7.82]
Studies not reported
Very low
Intervention not reported
Postoperative pain score: 1 year · participants aged 18‐60 years with myopia ranging in severity up to 12 diopters (D)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found